S. Foran, J. Wang, and P. Mitchell, Causes of incident visual impairment: The blue mountains eye study, Arch Ophthalmol, vol.120, pp.613-622, 2002.

N. Joachim, P. Mitchell, G. Burlutsky, A. Kifley, and J. J. Wang, The Incidence and Progression of Age-Related Macular Degeneration over 15 Years: The Blue Mountains Eye Study, Ophthalmology, vol.122, pp.2482-2491, 2015.

W. L. Wong, X. Su, X. Li, C. Cheung, R. Klein et al., Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis, Lancet Glob Health, vol.2, pp.106-122, 2014.

H. Buch, N. V. Nielsen, T. Vinding, G. B. Jensen, J. U. Prause et al., 14-Year Incidence, Progression, and Visual Morbidity of Age-Related Maculopathy: The Copenhagen City Eye Study, Ophthalmology, vol.112, pp.787-98, 2005.

C. A. Augood, J. R. Vingerling, and P. M. De-jong, Prevalence of age-related maculopathy in older europeans: The european eye study (eureye), Arch Ophthalmol, vol.124, pp.529-564, 2006.

R. Klein, B. Klein, M. D. Knudtson, S. M. Meuer, M. Swift et al., Fifteen-Year Cumulative Incidence of Age-Related Macular Degeneration: The Beaver Dam Eye Study, Ophthalmology, vol.114, pp.253-62, 2007.

F. Jonasson, D. E. Fisher, G. Eiriksdottir, S. Sigurdsson, R. Klein et al., Five-Year Incidence, Progression, and Risk Factors for Age-Related Macular Degeneration: The Age, Gene/Environment Susceptibility Study. Ophthalmology, vol.12, pp.1766-72, 2014.

J. M. Colijn, G. Buitendijk, E. Prokofyeva, D. Alves, M. L. Cachulo et al., Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future, Ophthalmology, vol.124, pp.1753-63, 2017.

A. R. Rudnicka, V. V. Kapetanakis, Z. Jarrar, A. K. Wathern, R. Wormald et al., Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis, Am J Ophthalmol, vol.160, pp.85-93, 2015.

M. G. Erke, G. Bertelsen, T. Peto, A. K. Sjølie, H. Lindekleiv et al., Prevalence of Agerelated Macular Degeneration in Elderly Caucasians: The Tromsø Eye Study, Ophthalmology, vol.119, pp.1737-1780, 2012.

J. B. Jonas, C. Cheung, P. , and S. , Updates on the Epidemiology of Age-Related Macular Degeneration, Asia-Pac J Ophthalmol, vol.6, pp.493-500, 2017.

A. Skaat, A. Chetrit, M. Belkin, M. Kinori, and O. Kalter-leibovici, Time trends in the incidence and causes of blindness in Israel, Am J Ophthalmol, vol.153, pp.214-235, 2012.

, The Eye Diseases Prevalence Research Group*. PRevalence of age-related macular degeneration in the united states, Arch Ophthalmol, vol.122, pp.564-72, 2004.

V. Parier and G. Soubrane, La dégénérescence maculaire liée à l'âge, Rev Médecine Interne, vol.29, pp.215-238, 2008.

S. Srinivasan, G. Swaminathan, V. Kulothungan, R. Raman, T. Sharma et al., Prevalence and the risk factors for visual impairment in age-related macular degeneration, Eye Lond Engl, vol.31, pp.846-55, 2017.

U. Chakravarthy, T. Y. Wong, A. Fletcher, E. Piault, C. Evans et al., Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis, BMC Ophthalmol, vol.10, p.31, 2010.

J. M. Seddon, R. E. Silver, M. Kwong, and B. Rosner, Risk Prediction for Progression of Macular Degeneration: 10 Common and Rare Genetic Variants, Demographic, Environmental, and Macular Covariates, Invest Ophthalmol Vis Sci, vol.56, pp.2192-202, 2015.

R. Klein, T. Peto, A. Bird, and M. R. Vannewkirk, The epidemiology of age-related macular degeneration, Am J Ophthalmol, vol.137, pp.486-95, 2004.

N. S. Abdelfattah, H. Zhang, D. S. Boyer, and S. R. Sadda, Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy, Retina, vol.36, pp.1843-50, 2016.

D. C. Fletcher and R. A. Schuchard, Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyond visual acuity, Optom Vis Sci, vol.83, pp.178-89, 2006.

J. S. Slakter and M. Stur, Quality of Life in Patients With Age-related Macular Degeneration: Impact of the Condition and Benefits of Treatment, Surv Ophthalmol, vol.50, pp.263-73, 2005.

B. W. Rovner and R. J. Casten, Activity loss and depression in age-related macular degeneration, Am J Geriatr Psychiatry, vol.10, pp.305-315, 2002.

B. Gopinath, G. Liew, G. Burlutsky, and P. Mitchell, Age-related macular degeneration and 5-year incidence of impaired activities of daily living, Maturitas, vol.77, pp.263-269, 2014.

B. L. Brody, A. C. Gamst, R. A. Williams, A. R. Smith, P. W. Lau et al., Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration, Ophthalmology, vol.108, pp.1893-900, 2001.

L. Sobrin and J. M. Seddon, Nature and nurture-genes and environment-predict onset and progression of macular degeneration, Prog Retin Eye Res, vol.40, pp.1-15, 2014.

I. Bhutto and G. Lutty, Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex, Mol Aspects Med, vol.33, pp.295-317, 2012.

S. S. Whitmore, E. H. Sohn, K. R. Chirco, A. V. Drack, E. M. Stone et al., Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy, Prog Retin Eye Res, vol.45, pp.1-29, 2015.

S. Datta, M. Cano, K. Ebrahimi, L. Wang, and J. T. Handa, The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD, Prog Retin Eye Res, vol.60, pp.201-219, 2017.

M. Dietzel, A. Farwick, and H. Hense, Genetic and risk factors for exudative AMD, Ophthalmologe, vol.107, pp.1103-1111, 2010.

R. Cascella, C. Strafella, V. Caputo, V. Errichiello, S. Zampatti et al., Towards the application of precision medicine in Age-Related Macular Degeneration, Prog Retin Eye Res, vol.63, pp.132-178, 2018.

I. A. Bhutto, T. Baba, C. Merges, V. Juriasinghani, D. S. Mcleod et al., C-reactive protein and complement factor H in aged human eyes and eyes with age-related macular degeneration, Br J Ophthalmol, vol.95, pp.1323-1353, 2011.

E. Ng and A. P. Adamis, Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration, Can J Ophthalmol, vol.40, pp.352-68, 2005.

I. A. Bhutto, D. S. Mcleod, T. Hasegawa, S. Y. Kim, C. Merges et al., Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration, Exp Eye Res, vol.82, pp.99-110, 2006.

K. J. Meyers, Z. Liu, A. E. Millen, S. K. Iyengar, B. A. Blodi et al., Joint Associations of Diet, Lifestyle, and Genes with Age-Related Macular Degeneration, Ophthalmology, vol.122, pp.2286-94, 2015.

J. Maller, S. George, S. Purcell, J. Fagerness, D. Altshuler et al., Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration, Nat Genet, vol.38, pp.1055-1064, 2006.

R. B. Bhisitkul, Vascular endothelial growth factor biology: clinical implications for ocular treatments, Br J Ophthalmol, vol.90, pp.1542-1549, 2006.

L. Lytvynchuk, A. Sergienko, G. Lavrenchuk, G. Petrovski, and . Antiproliferative, Apoptotic, and Autophagic Activity of Ranibizumab, Bevacizumab, Pegaptanib, and Aflibercept on Fibroblasts: Implication for Choroidal Neovascularization, J Ophthalmol, vol.2015, pp.934-63, 2015.

P. J. Rosenfeld, D. M. Brown, J. S. Heier, D. S. Boyer, P. K. Kaiser et al., Ranibizumab for Neovascular Age-Related Macular Degeneration, N Engl J Med, vol.355, pp.1419-1450, 2006.

P. Abraham, H. Yue, and W. L. Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2, Am J Ophthalmol, vol.150, pp.315-339, 2010.

H. Cho, M. L. Weber, C. P. Shah, and J. S. Heier, Initial utilization of aflibercept in exudative agerelated macular degeneration, Eur J Ophthalmol, vol.24, pp.576-81, 2014.

S. Sarwar, E. Clearfield, M. K. Soliman, M. A. Sadiq, A. J. Baldwin et al., Aflibercept for neovascular age-related macular degeneration, Cochrane Database Syst Rev, vol.2, p.11346, 2016.

S. S. Lynch and C. M. Cheng, Bevacizumab for neovascular ocular diseases, Ann Pharmacother, vol.41, pp.614-639, 2007.

J. Schouten, L. Heij, E. C. Webers, C. Lundqvist, I. J. Hendrikse et al., A systematic review on the effect of bevacizumab in exudative age-related macular degeneration, Graefes Arch Clin Exp Ophthalmol, vol.248, pp.453-454, 2010.

L. Arias, J. M. Caminal, L. Casas, C. Masuet, M. B. Badia et al., A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration, Br J Ophthalmol, vol.92, pp.1636-1677, 2008.

R. F. Spaide, K. Laud, H. F. Fine, J. M. Klancnik, C. B. Meyerle et al., Intravitreal bevacizumab treatment of choroidal neovascularisation secondary to age-related macular degeneration, Retina, vol.26, pp.383-90, 2006.

J. F. Arevalo, J. G. Sánchez, L. Wu, M. H. Berrocal, A. A. Alezzandrini et al., Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study, Ophthalmology, vol.117, pp.1974-81, 2010.

M. J. Goff, R. N. Johnson, H. R. Mcdonald, A. E. Jumper, J. M. Fu et al., Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration, Retina, vol.27, pp.432-440, 2007.

M. L. Bidot, L. Malvitte, S. Bidot, A. Bron, and C. Creuzot-garcher, Étude préliminaire sur l'efficacité de trois injections intravitréennes de bevacizumab dans le traitement de la dégénérescence maculaire liée à l'âge exsudative, J Fr Ophtalmol, vol.34, pp.376-81, 2011.

K. C. Madhusudhana, S. R. Hannan, C. Williams, S. V. Goverdhan, C. Rennie et al., Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases, Br J Ophthalmol, vol.91, pp.1716-1723, 2007.

M. G. Maguire, D. F. Martin, G. Ying, G. J. Jaffe, and E. Daniel, Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular AgeRelated Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials, Ophthalmology, vol.123, pp.1751-61, 2016.

U. Chakravarthy, S. P. Harding, C. A. Rogers, S. M. Downes, A. J. Lotery et al., Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial, The Lancet, vol.382, pp.1258-67, 2013.

P. Biswas, S. Sengupta, R. Choudhary, S. Home, A. Paul et al., Comparing ranibizumab with bevacizumab, Ophthalmology, vol.118, p.600, 2011.

M. L. Subramanian, G. Abedi, S. Ness, A. E. Fenberg, M. Daly et al., Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial, Eye Lond Engl, vol.24, pp.1708-1723, 2010.

I. Krebs, L. Schmetterer, A. Boltz, R. Told, V. Vécsei-marlovits et al., A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration, Br J Ophthalmol, vol.97, pp.266-71, 2013.

L. Kodjikian, E. H. Souied, G. Mimoun, M. Mauget-faÿsse, F. Behar-cohen et al., Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial, Ophthalmology, vol.120, pp.2300-2309, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01814467

S. D. Solomon, K. B. Lindsley, M. G. Krzystolik, S. S. Vedula, and B. S. Hawkins, Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: Findings from a Cochrane Systematic Review, Ophthalmology, vol.123, pp.70-77, 2016.

E. Poku, J. Brazier, J. Carlton, and A. Ferreira, Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review, BMC Ophthalmol, vol.13, p.74, 2013.

J. Raftery, A. Clegg, J. Jones, S. C. Tan, A. Lotery et al., Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness, Br J Ophthalmol, vol.91, pp.1244-1250, 2007.

J. J. Patel, M. Mendes, M. Bounthavong, M. Christopher, D. Boggie et al., Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model, J Eval Clin Pract, vol.18, pp.247-55, 2012.

T. Butt, A. Lee, C. Lee, and A. Tufail, The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes, BMJ Open, vol.5, issue.5, 2015.

S. J. Walters and J. E. Brazier, Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D, Qual Life Res, vol.14, pp.1523-1555, 2005.

K. Tsiplova, E. Pullenayegum, T. Cooke, and F. Xie, EQ-5D-derived health utilities and minimally important differences for chronic health conditions: 2011 Commonwealth Fund Survey of Sicker Adults in Canada, Qual Life Res, vol.25, pp.3009-3016, 2016.

J. Chevalier and G. De-pouvourville, Valuing EQ-5D using time trade-off in France, Eur J Health Econ, vol.14, pp.57-66, 2013.

R. Deonandan and S. Jones, Anti-Vascular Endothelial Growth Factor Drugs for the Treatment of Retinal Conditions: A Review of the Safety

. Ottawa, Canadian Agency for Drugs and Technologies in Health, 2017.

C. Del-giovane, L. Vacchi, D. Mavridis, G. Filippini, and G. Salanti, Network meta-analysis models to account for variability in treatment definitions: application to dose effects, Stat Med, vol.32, pp.25-39, 2013.

R. K. Owen, D. G. Tincello, and R. A. Keith, Network meta-analysis: development of a three-level hierarchical modeling approach incorporating dose-related constraints, Value Health, vol.18, pp.116-142, 2015.

J. K. Schmier and C. K. Hulme-lowe, Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges, PharmacoEconomics, vol.34, pp.259-72, 2016.

B. Wu, J. Li, H. Lin, and H. Wu, Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation, J Ophthalmol, 2016.

H. Tamura, R. Goto, Y. Akune, Y. Hiratsuka, S. Hiragi et al., The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study, PloS One, vol.10, p.133628, 2015.

H. Li, X. Li, and F. Xie, Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration, Zhonghua Yan Ke Za Zhi Chin J Ophthalmol, vol.50, pp.426-459, 2014.

M. Espallargues, C. J. Czoski-murray, N. J. Bansback, J. Carlton, G. M. Lewis et al., The impact of age-related macular degeneration on health status utility values, Invest Ophthalmol Vis Sci, vol.46, pp.4016-4039, 2005.

N. Bansback, C. Czoski-murray, C. J. Lewis, G. Hughes, L. Espallargues et al., Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity, Qual Life Res, vol.16, pp.533-576, 2007.

J. Sahel, F. Bandello, A. A. Maurel, F. Negrini, C. Berdeaux et al., Healthrelated quality of life and utility in patients with age-related macular degeneration, Arch Ophthalmol, vol.125, pp.945-51, 2007.

J. D. Stein, P. A. Newman-casey, T. Mrinalini, P. P. Lee, and D. W. Hutton, Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration, Ophthalmology, vol.121, pp.936-981, 2014.

F. Elias, E. N. Silva, . Da, R. Belfort, M. T. Silva et al., Treatment Options for AgeRelated Macular Degeneration: A Budget Impact Analysis from the Perspective of the Brazilian Public Health System, PloS One, vol.10, p.139556, 2015.

W. Hodge, A. Brown, S. Kymes, A. Cruess, G. Blackhouse et al., Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation, Can J Ophthalmol, vol.45, pp.223-253, 2010.

P. Vottonen and E. Kankaanpää, Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model, Acta Ophthalmol, vol.94, pp.652-658, 2016.

H. A. Dakin, S. Wordsworth, C. A. Rogers, G. Abangma, J. Raftery et al., Costeffectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial, BMJ Open, 2014.

F. Van-asten, C. Michels, C. B. Hoyng, G. J. Van-der-wilt, B. J. Klevering et al., The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective, PloS One, vol.13, p.197670, 2018.

T. A. Moreno and S. J. Kim, Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health, Semin Ophthalmol, vol.31, pp.378-84, 2016.

S. Piermarocchi, M. Varano, M. Parravano, F. Oddone, M. Sartore et al., Quality of Vision Index: a new method to appraise visual function changes in age-related macular degeneration, Eur J Ophthalmol, vol.21, pp.55-66, 2011.

M. K. Schmid, L. M. Bachmann, L. Fäs, A. G. Kessels, O. M. Job et al., Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis, Br J Ophthalmol, vol.99, pp.141-147, 2015.

E. Poku, J. Rathbone, R. Wong, E. Everson-hock, M. Essat et al., The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review, BMJ Open, vol.4, issue.7, 2014.

R. Nuzzi and F. Tridico, Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study, Semin Ophthalmol, vol.30, pp.129-164, 2015.

D. K. Sigford, S. Reddy, C. Mollineaux, and S. Schaal, Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis, Clin Ophthalmol, vol.9, pp.773-81, 2015.

R. Merani and A. P. Hunyor, Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review, Int J Retina Vitr

. Jul, , vol.1, 2016.

H. Shimada, T. Hattori, R. Mori, H. Nakashizuka, K. Fujita et al., Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask, Graefes Arch Clin Exp Ophthalmol, vol.251, pp.1885-90, 2013.

C. M. Schmucker, G. Rücker, H. Sommer, G. Virgili, Y. K. Loke et al., Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular AgeRelated Macular Degeneration: A Systematic Review and Meta-Analysis, PloS One, vol.10, p.137866, 2015.

C. Biagi, V. Conti, N. Montanaro, M. Melis, E. Buccellato et al., Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions, Eur J Clin Pharmacol, vol.70, pp.1505-1517, 2014.

D. S. Fong, P. Custis, J. Howes, and J. Hsu, Intravitreal bevacizumab and ranibizumab for agerelated macular degeneration a multicenter, retrospective study, Ophthalmology, vol.117, pp.298-302, 2010.

S. Sharma, D. Johnson, M. Abouammoh, S. Hollands, and A. Brissette, Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections, Can J Ophthalmol, vol.47, pp.275-284, 2012.

M. Abouammoh and S. Sharma, Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration, Curr Opin Ophthalmol, vol.22, pp.152-160, 2011.

D. Johnson and S. Sharma, Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration, Curr Opin Ophthalmol, vol.24, pp.205-217, 2013.

W. Wang, J. Chen, X. Zhang, M. Yao, X. Liu et al., Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis, Int J Ophthalmol, vol.8, pp.138-185, 2015.

L. Moja, E. Lucenteforte, K. H. Kwag, V. Bertele, A. Campomori et al., Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration, Cochrane Database Syst Rev, vol.9, p.11230, 2014.

K. Berg, E. Hadzalic, I. Gjertsen, V. Forsaa, L. H. Berger et al., Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results, Ophthalmology, vol.123, pp.51-60, 2016.

A. Schauwvlieghe, G. Dijkman, J. M. Hooymans, F. D. Verbraak, C. B. Hoyng et al., Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study, PLoS ONE

. May, , vol.11, 2016.

D. Ng, A. Kwok, J. Tong, C. Chan, and W. Li, Bevacizumab for neovascular age-related macular degeneration in Chinese patients in a clinical setting, Int J Ophthalmol, vol.9, pp.424-454, 2016.

X. Feng, I. J. Constable, I. L. Mcallister, and T. Isaacs, Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration, Int J Ophthalmol, vol.4, pp.85-93, 2011.

G. Chen, W. Li, R. Tzekov, F. Jiang, S. Mao et al., Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials, Retina, vol.35, pp.187-93, 2015.

K. Berg, T. R. Pedersen, L. Sandvik, and R. Bragadóttir, Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol, Ophthalmology, vol.122, pp.146-52, 2015.

M. V. Emerson, A. K. Lauer, C. J. Flaxel, D. J. Wilson, P. J. Francis et al., Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration, Retina, vol.27, pp.439-483, 2007.

F. G. Holz, W. Amoaku, J. Donate, R. H. Guymer, U. Kellner et al., Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study, Ophthalmology, vol.118, pp.663-71, 2011.

G. A. Lalwani, P. J. Rosenfeld, A. E. Fung, S. R. Dubovy, S. Michels et al., A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study, Am J Ophthalmol, vol.148, pp.43-58, 2009.

D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy et al., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study, Ophthalmology, vol.116, pp.57-65, 2009.

U. Chakravarthy, S. P. Harding, C. A. Rogers, S. Downes, A. J. Lotery et al., A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN), Health Technol Assess, vol.19, pp.1-298, 2015.

M. G. Maguire, D. F. Martin, G. Ying, G. J. Jaffe, E. Daniel et al., Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular AgeRelated Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials, Ophthalmology, 2016.

U. Schmidt-erfurth, V. Chong, A. Loewenstein, M. Larsen, E. Souied et al., Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA), Br J Ophthalmol, vol.98, issue.9, pp.1144-67, 2014.

E. Maringe, E. Letesson, A. Duncombe, M. Muraine, and O. Genevois, Evaluation of the efficacy of aflibercept's in the treatment of neovascular age-related macular degeneration in treatment-naive and switched patients, J Fr Ophtalmol, vol.39, pp.255-60, 2016.

, Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial, JAMA, vol.309, pp.2005-2020, 2013.

R. J. Olk, E. Peralta, D. L. Gierhart, G. C. Brown, and M. M. Brown, Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis, Int J Retina Vitreous, vol.1, p.22, 2015.

G. C. Brown, M. M. Brown, H. B. Lieske, P. A. Lieske, and K. S. Brown, A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration, Int J Retina Vitreous, vol.1, p.19, 2015.

E. L. Ross, D. W. Hutton, J. D. Stein, N. M. Bressler, L. M. Jampol et al., Costeffectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial, JAMA Ophthalmol, vol.134, pp.888-96, 2016.

D. Iturralde, R. F. Spaide, C. B. Meyerle, J. M. Klancnik, L. A. Yannuzzi et al., Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study, Retina, vol.26, pp.279-84, 2006.

P. Iacono, M. B. Parodi, A. Papayannis, S. Kontadakis, S. Sheth et al., Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization, Retina, vol.32, pp.1539-1585, 2012.

P. J. Rosenfeld, M. A. Windsor, W. J. Feuer, S. Sun, K. D. Frick et al., Estimating Medicare and patient savings from the use of bevacizumab for the treatment of exudative age-related macular degeneration, Am J Ophthalmol, vol.191, pp.135-174, 2018.

R. Parikh, J. S. Ross, L. R. Sangaralingham, R. A. Adelman, N. D. Shah et al., Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients, Ophthalmology, vol.124, pp.352-360, 2017.

, Étapes méthodologiques d'élaboration du projet de recherche médico-économique évaluant les traitements anti-VEGF dans le traitement de la dégénérescence maculaire liée à l'âge

, Introduction: Les coûts liés aux traitements de la Dégénérescence maculaire Liée À l'Age (DMLA) constituent une des premières dépenses de santé. Le Bevacizumab présente un coût moindre par rapport aux autres traitements. L'impact médico-économique du traitement de la DMLA

. France, L'objectif était d'exposer les différentes étapes méthodologiques de l'élaboration d'un Projet de

, Un PRME comprenait deux axes : « innovation en santé » pour démontrer l'efficience des technologies de santé, et « parcours de soins » comparant en vie réelle l'efficience des stratégies de prise en charge fondées sur des technologies de santé. Résultats: Ce projet visait à partir d'une modélisation économique à réaliser une analyse coût/utilité des modalités de prise en charge de la DMLA exsudative. Deux sous études étaient associées : 1) l'analyse de type micro-costing de la préparation des seringues de Bevacizumab et 2) l'évaluation non interventionnelle, multicentrique, prospective et transversale des scores d'utilité basés sur des niveaux d'acuité visuelle, de qualité de vie et de tous les coûts liés à la prise en charge. Discussion: L'évaluation de nos pratiques est primordiale de nos jours ; afin d'assurer la pérennisation de notre système de santé. La méthodologie d'un PRME doit être adaptée afin d'en tirer des conclusions fiables. Conclusion: Celles-ci sont évaluées, Recherche Médico-Economique (PRME). Matériel et méthodes: La lettre d'intention synthétisait les principales caractéristiques de la recherche

. Mots-clés, Projet de Recherche Médico-Économique, Méthodologie, Analyse Coût/Utilité, Dégénérescence Maculaire Liée à l'Age, Bevacizumab